Targeted therapy in the treatment of malignant gliomas

References

• LouisDNOhgakiHWiestlerODCaveneeWKWHO Classification of Tumors of the Central Nervous System4th editionLyon, FranceInternational Agency For Research on Cancer2007
   Google Scholar
• WongAJBignerSHBignerDDKinzlerKWHamiltonSRVogelsteinBIncreased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplificationProc Natl Acad Sci U S A19878419689969033477813
   PubMed Web of Science ®Google Scholar
• WickstrandCJMcClendonREFriedmanAHBignerDDCell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIIICancer Res19975718413041409307304
   PubMed Web of Science ®Google Scholar
• BiernatWHuangHYokooHKleihuesPOhgakiHPredominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomasBrain Pathol200414213113615193025
   PubMed Web of Science ®Google Scholar
• PelloskiCEBallmanKVFurthAFEpidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastomaJ Clin Oncol200725162288229417538175
   PubMed Web of Science ®Google Scholar
• ShinojimaNTadaKSiraishiSPrognostic value of epidermal growth factor receptor in patients with glioblastoma multiformeCancer Res200363206962697014583498
   PubMed Web of Science ®Google Scholar
• ReifenbergerJReifenbergerGIchimuraKSchmidtEEWechlerWCollinsVPEpidermal growth factor expression in oligodendroglial tumorsAm J Pathol1996149129358686753
   PubMed Web of Science ®Google Scholar
• ChakravartiASeiferheldWTuXImmunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology GroupInt J Radiat Oncol Biol Phys200562231832715890570
   PubMed Web of Science ®Google Scholar
• YardenYShilohBZSnapshot: EGFR signaling pathwayCell20071315101818045542
   PubMed Web of Science ®Google Scholar
• YuanTLCantleyLCPI3K pathway alterations in cancer: variations on a themeOncogene200827415497551018794884
   PubMed Web of Science ®Google Scholar
• VivancoISawyersCLThe phosphatidylinositol 3-kinase Akt pathway in human cancerNat Rev Cancer20022748950112094235
   PubMed Web of Science ®Google Scholar
• EndersbyRBakerSJPTEN signaling in brain: neuropathology and tumorigenesisOncogene2008275416543018794877
   PubMed Web of Science ®Google Scholar
• MellinghoffIKWangMYVivancoIMolecular determinants of the response of glioblastomas to EGFR kinase inhibitorsN Engl J Med2005353192012202416282176
   PubMed Web of Science ®Google Scholar
• Haas-KoganDAPradosMDTihanTEpidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinibJ Natl Cancer Inst2005971288088715956649
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med2005352878679215728811
   PubMed Web of Science ®Google Scholar
• GalliaGLRandVSiuI-MPIK3CA gene mutations in pediatric and adult glioblastoma multiformeMol Cancer Res200641070971417050665
   PubMed Web of Science ®Google Scholar
• BroderickDKDiCParrettTJMutations of PI3KCA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomasCancer Res200464155048505015289301
   PubMed Web of Science ®Google Scholar
• LiuRTianBGearingMHunterSYeKMaoZCdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasionProc Natl Acad Sci U S A2008105217570757518487454
   PubMed Web of Science ®Google Scholar
• SchullerURuiterMHermsJKretzschmarHAGrabson-FrodlEAbsence in the mutations to AKT1 oncogene in glioblastomas and medulloblastomasActa Neuropathol2008115336736818172656
   PubMed Web of Science ®Google Scholar
• FaillotTMagdelenatHMadyEA phase one study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomasNeurosurgery19963934784838875477
   PubMed Web of Science ®Google Scholar
• StragliottoGVegaFStasieskiPGroppPPoissonMDelattreJYMultiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomasEur J Cancer199632A46366408695267
   PubMed Web of Science ®Google Scholar
• RamosTCFigueredoJCatalaMTreatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trialCancer Biol Ther20065437537916575203
   PubMed Web of Science ®Google Scholar
• WigodaZKulaDBierzynska-MacyszynzGUse of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumorsHybridoma (Larchmt)200625312513216796458
   PubMedGoogle Scholar
• CombsSEHeegerSHaselmannREdlerLDebusJSchulz-ErtnerDtreatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) – phase I/II trial: study protocolBMC Cancer2006613316709245
   PubMed Web of Science ®Google Scholar
• YangWWuGBarthRFMolecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodiesClin Cancer Res200814388389118245552
   PubMed Web of Science ®Google Scholar
• CasacoALopezGGarciaIPhase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade gliomaCancer Biol Ther20087333333918094616
   PubMed Web of Science ®Google Scholar
• SampsonJHArcherGEMitchellDAHeimbergerABBignerDDTumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant gliomaSemin Immunol200820526727518539480
   PubMed Web of Science ®Google Scholar
• HeimbergerABCrottyLEArcherGEHessKRWickstrandCJFriedmanAHEpidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumorsClin Cancer Res20039114247425414519652
   PubMed Web of Science ®Google Scholar
• DohertyLGigasDCKesariSPilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomasNeurology200667115615816832099
   PubMed Web of Science ®Google Scholar
• ErmoianRPKaprealianTLambornKRSignal transduction molecules in gliomas of all gradesJ Neurooncol2009911192618759130
   PubMed Web of Science ®Google Scholar
• ParryLMaynardJHPatelAMolecular analysis of the TSC1 and TSC2 tumor suppressor genes in sporadic glial and glioneuronal tumorsHum Genet2000107435035611129334
   PubMed Web of Science ®Google Scholar
• SorensonAGBatchelorTTWenPYZhangWTJainRKResponse criteria for gliomaNat Clin Pract Oncol200851163464418711427
   PubMedGoogle Scholar
• GalanisEBucknerJCMaurerMJPhase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group studyJ Clin Oncol200523235294530415998902
   PubMed Web of Science ®Google Scholar
• ChangSMWenPCloughesyTPhase II study of CCI-779 in patients with recurrent glioblastoma multiformeInvest New Drugs200523435736116012795
   PubMed Web of Science ®Google Scholar
• ShinoharaETCaoCNiermannKEnhanced radiation damage of tumor vasculature by mTOR inhibitorsOncogene200524355414542215940265
   PubMed Web of Science ®Google Scholar
• GoudarRKShiQHjelmelandMDCombination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibitionMol Cancer Ther20054110111215657358
   PubMed Web of Science ®Google Scholar
• KnobbeCBReifenbergerJReifenbergerGMutation analysis of the Ras pathway genes NRAS, HRAS, KRAS, and BRAF in glioblastomasActa Neuropathol2004108646747015517309
   PubMed Web of Science ®Google Scholar
• SebtiSMProtein farnesylation: implications for normal physiology, malignant transformation, and cancer therapyCancer Cell20057429730015837619
   PubMed Web of Science ®Google Scholar
• JeukenJvan den BroeckeCGijsenSBoots-SprengerSWesselingPRas/Raf pathway activation in gliomas: the result of copy number gains rather than activating mutationsActa Neuropathol2007114212113317588166
   PubMed Web of Science ®Google Scholar
• FeldkampMMLauNRoncariLGuhaAIsotype-specific Ras.GTPlevels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational statusCancer Res200161114425443111389071
   PubMed Web of Science ®Google Scholar
• FeldkampMMLalaPLauNRoncariLGuhaAExpression of activated epidermal growth factor receptors Ras-guanosine triphosphate and mitogen-activated protein kinase in human glioblastoma multiforme specimensNeurosurgery19994561442145310598712
   PubMed Web of Science ®Google Scholar
• ChakravartiAChakladarADelaneyMALathamDELoefflerLSThe epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a Ras-dependant mannerCancer Res200262154307431512154034
   PubMed Web of Science ®Google Scholar
• Haas-KoganDABanerjeeAKocakMPhase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem gliomaNeuro Oncol200810334134718417739
   PubMed Web of Science ®Google Scholar
• MoyalECLaprieADellanesMPhase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiformeInt J Radiat Oncol Biol Phys20076851396140117570606
   PubMed Web of Science ®Google Scholar
• CloughesyTFKuhnJRobbinsHIPhase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing anti-epileptic drugs: a North American Brain Tumor Consortium StudyJ Clin Oncol200624223651365616877733
   PubMed Web of Science ®Google Scholar
• CloughesyTFWenPYRobbinsHIPhase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium StudyJ Clin Oncol200624223651365616877733
   PubMed Web of Science ®Google Scholar
• FouladiMNicholsonHSZhouTA phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children’s Oncology Group studyCancer2007110112535254117932894
   PubMed Web of Science ®Google Scholar
• LarnerJJaneJLawsEPackerRMyersCShaffreyMA phase I–II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiformeAm J Clin Oncol19982165795839856659
   PubMed Web of Science ®Google Scholar
• LustigRMikkelsonTLesserGPhase II pre-radiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing diseaseNeuro Oncol20081061004100918725460
   PubMed Web of Science ®Google Scholar
• KazantsevAGThompsenLMTherapeutic application of histone deacetylase inhibitors for central nervous system disordersNat Rev Drug Discov200871085486818827828
   PubMed Web of Science ®Google Scholar
• da FonescaCOLindenRFuturoDGattassCRQuirico-SantosTRas pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcoholArch Immunol Ther Exp2008564267276
   Web of Science ®Google Scholar
• SmithKTWorkmanJLHistone deacetylase inhibitors: anticancer compoundsInt J Biochem Cell Biol2008doi:10.1016j.biocel.2008.09.008
   Web of Science ®Google Scholar
• SudakinVYenTJTargeting mitosis for anti-cancer therapyBiodrugs200721422523317628120
   PubMed Web of Science ®Google Scholar
• YinDOngGMHuJSuberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivoClin Cancer Res20071331045105217289901
   PubMed Web of Science ®Google Scholar
• CamphausenKCernaDScottTEnhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acidInt J Cancer2005114338038615578701
   PubMed Web of Science ®Google Scholar
• PhielCJZhangFHuangEYGuentherMGLazarMAKleinPSHistone deacetlyase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogenJ Biol Chem200127639367343674111473107
   PubMed Web of Science ®Google Scholar
• AppelsNMBeijnenJHSchellensJHDevelopment of farnesyl transferase inhibitors: a reviewOncologist200510856557816177281
   PubMed Web of Science ®Google Scholar
• ZujewskiJHorakIDBolCJPhase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancerJ Clin Oncol200018492794110673536
   PubMed Web of Science ®Google Scholar
• JonesHAHahnSMBernhardEMcKennaWGRas inhibitors and radiation therapySemin Radiat Oncol200111432833711677657
   PubMed Web of Science ®Google Scholar
• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med197128521118211864938153
   PubMed Web of Science ®Google Scholar
• WhiteCWSondheimerHMCrouchECWilsonHFanLLTreatment of pulmonary hemangiomatosis with recombinant interferon alpha-2aN Engl J Med198932018119712002710192
   PubMed Web of Science ®Google Scholar
• FrederickLWangXYEleyGJamesCDDiversity and frequency of epidermal growth factor receptor mutations in human glioblastomasCancer Res20006051383138710728703
   PubMed Web of Science ®Google Scholar
• BremSCotranRFolkmanJTumor angiogenesis: a quantitative method for histologic gradingJ Natl Cancer Inst19724823473564347034
   PubMed Web of Science ®Google Scholar
• DasSSrikanthMKesslerJACancer stem cells and gliomaNat Clin Pract Neurol20084842743518628751
   PubMedGoogle Scholar
• WakabayashiTKayamaTNishikawaRA multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study)Jpn J Clin Oncol2008381071571818845525
   PubMed Web of Science ®Google Scholar
• BucknerJCSchombergPJMcGinnisWLA phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade gliomaCancer200192242043311466698
   PubMed Web of Science ®Google Scholar
• DillmanROSheaWMTaiDFInterferon-alpha2a and 13-cis-retinois acid with radiation treatment for high grade gliomaNeuro Oncol200131354111305415
   PubMed Web of Science ®Google Scholar
• ChangSMBarkerFG2ndHuhnSLHigh dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent gliomaJ Neurooncol19983721691769524096
   PubMed Web of Science ®Google Scholar
• D’AmatoRJLoughnanMSFlynnEFolkmanJThalidomide is an inhibitor of angiogenesisProc Natl Acad Sci U S A1994919408240857513432
   PubMed Web of Science ®Google Scholar
• SampaioEPSarnoENGalillyRCohnZAKaplanGThalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytesJ Exp Med199117336997031997652
   PubMed Web of Science ®Google Scholar
• ChangSMLambornKRMalecMPhase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiformeInt J Radiat Oncol Biol Phys200460235335715380566
   PubMed Web of Science ®Google Scholar
• KesariSSchiffDHensonJWPhase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adultsNeuro Oncol200810330030818403492
   PubMed Web of Science ®Google Scholar
• KowanetzMFerraraNVascular endothelial growth factor signaling pathways: therapeutic perspectiveClin Cancer Res200612175018502216951216
   PubMed Web of Science ®Google Scholar
• ShibuyaMVascular endothelial growth factor-dependant and – independent regulation of angiogenesisBMB Rep200841427828618452647
   PubMed Web of Science ®Google Scholar
• KaurBTanCBratDJPostDEVan MeirEGGenetic and hypoxic regulation of angiogenesis in gliomasJ Neurooncol200470222924315674480
   PubMed Web of Science ®Google Scholar
• ChenWDelaloyeSSilvermanDHPredicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot studyJ Clin Oncol200725304714472117947718
   PubMed Web of Science ®Google Scholar
• BartlettJBDredgeKDalgleishAGThe evolution of thalidomide and its IMiD derivatives as anticancer agentsNat Rev Cancer20044431432215057291
   PubMed Web of Science ®Google Scholar
• DredgeKHorsfallRRobinsonSPOrally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitroMicrovasc Res2005691–2566315797261
   PubMed Web of Science ®Google Scholar
• FineHAKimLAlbertPSA phase I trial of lenalidomide in patients with recurrent primary central nervous system tumorsClin Cancer Res200713237101710618056189
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res20071341253125917317837
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol200725304722472917947719
   PubMed Web of Science ®Google Scholar
• CloughesyTFA phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent treatment-refractory glioblastoma (GBM)ASCO Meeting Abstract2008No. 2010b
   Google Scholar
• ZunigaRMTorcuatorRJainREfficacy, safety, and patterns of response and recurrence in patients with high-grade gliomas treated with bevacizumab plus irinotecanJ Neurooncol200991332933618953493
   PubMed Web of Science ®Google Scholar
• LaiAFilkaEMcGibbonBPhase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerabilityInt J Radiat Oncol Biol Phys20087151372138018355978
   PubMed Web of Science ®Google Scholar
• SathornsumeteeSCaoYMarcelloJETumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecanJ Clin Oncol200826227127818182667
   PubMed Web of Science ®Google Scholar
• Gomez-ManzanoCHolashJFueyoJVEGF Trap induces antiglioma effect at different stages of diseaseNeuro Oncol200810694094518708344
   PubMed Web of Science ®Google Scholar
• BatchelorTTSorensonAGdi TomasoEAZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsCancer Cell2007111839517222792
   PubMed Web of Science ®Google Scholar
• HarlandSPKucREPickardJDDavenportAPCharacterization of endothelin receptors in human brain cortex, gliomas, and meningiomasJ Cardiovasc Phamacol199526Suppl 3S408S411
   Google Scholar
• SpinellaFRosanoSDiCastorVEndothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cellsCancer Res20076741725173417308114
   PubMed Web of Science ®Google Scholar
• PhuphanichSCarsonKAGrossmanSAPhase I safety study of escalating doses of atrasentan in adults with recurrent malignant gliomaNeuro Oncol200810461762318477765
   PubMed Web of Science ®Google Scholar
• GuzmanMDuarteMJBlazquezCA pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiformeBr J Cancer200695219720316804518
   PubMed Web of Science ®Google Scholar
• ReardonDAQuinnJAVredenburghJPhase II trial of irinotecan plus celecoxib in adults with recurrent malignant gliomaCancer2005103232933815558802
   PubMed Web of Science ®Google Scholar
• AvraamidesCJGarmy-SusiniBVarnerJAIntegrins in angiogenesis ad lymphangiogenesisNat Rev Cancer20088860461718497750
   PubMed Web of Science ®Google Scholar
• NaborsLBMikkelsonTRosenfeldSSPhase I and correlative biology study of cilengitide in patients with recurrent malignant gliomaJ Clin Oncol200725131651165717470857
   PubMed Web of Science ®Google Scholar
• MacDonaldTJStewartCFKocakMPhase I clinical trial of celengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012J Clin Oncol200826691992418281665
   PubMed Web of Science ®Google Scholar
• SanaiNAlvarez-BullyaABergerMSNeural stem cells and the origin of gliomasN Engl J Med2005353881182216120861
   PubMed Web of Science ®Google Scholar
• SanaiNTramontinADQuinones-HinojosaAUnique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migrationNature2004427697674074414973487
   PubMed Web of Science ®Google Scholar
• ErikssonPPerfilievaEBjork-ErikksonTNeurogenesis in the adult human hippocampusNat Med19841113131317
   Web of Science ®Google Scholar
• BaoSWuQMcClendonREGlioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature2006444712075676017051156
   PubMed Web of Science ®Google Scholar
• RichJNCancer stem cells in radiation resistanceCancer Res200767198980898417908997
   PubMed Web of Science ®Google Scholar
• GrifferoFDagaAMarrubiDDifferent response of human glioma tumor-initiating cells to EGFR kinase inhibitorsJ Biol Chem2009284117138714819147502
   PubMed Web of Science ®Google Scholar
• EylerCEFooWCLaFiuraKMMcLendonREHjelmelandABRichJNBrain cancer stem cells display sensitivity to Akt inhibitionStem Cells200826123027302618802038
   PubMed Web of Science ®Google Scholar
• BaoSWuQLiZTargeting cancer stem cells through L1CAM suppresses glioma growthCancer Res200868156043604818676824
   PubMed Web of Science ®Google Scholar
• AboodyKSBrownARainovNGNeural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomasProc Natl Acad Sci U S A20009723128461285111070094
   PubMed Web of Science ®Google Scholar
• AboodyKSNajbauerJDanksMKStem and progenitor cell-mediated tumor selective gene therapyGene Ther2008151073975218369324
   PubMed Web of Science ®Google Scholar
• ZhaoDNajbauerJGarciaENeural cell tropism to glioma: critical role of tumor hypoxiaMol Cancer Res20086121819182919074827
   PubMed Web of Science ®Google Scholar
• TylerMAUlasovIVSonabendAMNeural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivoGene Ther200916226227819078993
   PubMed Web of Science ®Google Scholar
• SonabendAMUlasovIVTylerMARiveraAAMathisJMLesniakMSMesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial gliomaStem Cells200826383184118192232
   PubMed Web of Science ®Google Scholar
• DentPYacoubAParkMSearching for a cure: gene therapy for glioblastomaGene Ther20087913351340
   Google Scholar
• LangFFBrunerJMFullerGNPhase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical resultsJ Clin Oncol200321132508251812839017
   PubMed Web of Science ®Google Scholar
• KlatzmannDValeryCABensimonGA phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma: Study Group on Gene Therapy for GlioblastomaHum Gene Ther1998917259526049853526
   PubMed Web of Science ®Google Scholar
• RainovNGA phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiformeHum Gene Ther200011172389240111096443
   PubMed Web of Science ®Google Scholar
• EckSLAlaviJBJudyKTreatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trialHum Gene Ther20011219711311177547
   PubMed Web of Science ®Google Scholar
• ColomboFBarzonLFranchinECombined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical resultsCancer Gene Ther2005121083584815891772
   PubMed Web of Science ®Google Scholar
• RenHBoulikasTLundstromKImmunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene – a phase I/II clinical protocolJ Neurooncol2008641–214715412952295
   PubMed Web of Science ®Google Scholar
• OkadaHPollackIFLiebermanFGene therapy of malignant gliomas: a pilot study of vaccination with autologous irradiated glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune responseHum Gene Ther200112557559511268289
   PubMed Web of Science ®Google Scholar
• LassmanABRossiMRRaizerJJMolecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01–03 and 00–01Clin Cancer Res200511217841785016278407
   PubMed Web of Science ®Google Scholar
• PradosMDLambornKRChangSPhase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant gliomaNeuro Oncol200681677816443950
   PubMed Web of Science ®Google Scholar
• PreusserMGelpiERottenfusserAEpithelial growth factor receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory studyJ Neurooncol200889221121818458820
   PubMed Web of Science ®Google Scholar
• FranceshiECavalloGLonardiSGefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)Br J Cancer20079671047105117353924
   PubMed Web of Science ®Google Scholar
• de GrootJFGilbertMRAldapeKPhase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastomaJ Neurooncol2008901899718581057
   PubMed Web of Science ®Google Scholar
• BrownPDKrishnanSSarkariaJNPhase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group study N1077J Clin Oncol200826345603560918955445
   PubMed Web of Science ®Google Scholar
• KrishnanSBrownPDBallmanKVPhase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177Int J Radiat Oncol Biol Phys20066541192119916626884
   PubMed Web of Science ®Google Scholar
• SchwerALDamekDMKavanaghBDA phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomasInt J Radiat Oncol Biol Phys2008704993100117967517
   PubMed Web of Science ®Google Scholar
• RichJNReardonDAPeeryTPhase II trial of gefitinib in recurrent glioblastomaJ Clin Oncol200422113314214638850
   PubMed Web of Science ®Google Scholar
• ReardonDAQuinnJAVredenburghJJPhase I trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaClin Cancer Res200612386086816467100
   PubMed Web of Science ®Google Scholar
• PradosMDYungWKAWenPYPhase-I trial of gefitinib and temozolomide in patients with malignant glioma: a North American Brain Tumor Consortium studyCancer Chemother Pharmacol20086161059106717694310
   PubMed Web of Science ®Google Scholar
• PreusserMGelpiERottenfusserAEpithelial growth factor receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory studyJ Neurooncol200889221121818458820
   PubMed Web of Science ®Google Scholar